Bliss GVS Pharma falls on getting 3 minor observations from USFDA for manufacturing unit in Palghar
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Bliss GVS Pharma is currently trading at Rs. 73.48, down by 1.71 points or 2.27% from its previous closing of Rs. 75.19 on the BSE.
The scrip opened at Rs. 71.30 and has touched a high and low of Rs. 76.88 and Rs. 71.30 respectively. So far 7826 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 91.35 on 08-Sep-2022 and a 52 week low of Rs. 66.25 on 29-Mar-2022.
Last one week high and low of the scrip stood at Rs. 77.88 and Rs. 71.30 respectively. The current market cap of the company is Rs. 766.36 crore.
The promoters holding in the company stood at 34.46%, while Institutions and Non-Institutions held 23.16% and 42.38% respectively.
United States Food and Drug Administration (USFDA) has conducted a Pre-Approval Inspection (PAI) and Good Manufacturing Practice (GMP) inspection at Bliss GVS Pharma’s manufacturing unit at Dewan Udyog Nagar, Aliyali Village, Palghar, Maharashtra from March 13, 2023 to March 17, 2023. After the inspection, the USFDA issued a Form 483 with 3 minor observations.
The observations are procedural in nature. The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations.
Bliss GVS Pharma is a fast-growing Pharmaceutical Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market.
